Navigation Links
Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results
Date:2/27/2012

J2507, by the Centers for Medicare and Medicaid Services for KRYSTEXXA, which became effective on January 1, 2012.
  • Presented new data surrounding KRYSTEXXA and the impact of refractory chronic gout at The American College of Rheumatology Meeting.

  • Launched a new educational campaign, "Check Out Your Gout," to raise awareness about gout and a severe form of the condition known as RCG.

  • Financial Results of Operations for the Three Months Ended December 31, 2011Total revenues increased by $2.7 million, or 286%, to $3.7 million for the three months ended December 31, 2011, from $1.0 million for the three months ended December 31, 2010. The higher net sales for the three months ended December 31, 2011 were the result of the Company's launch of KRYSTEXXA, which generated $3.0 million in net sales for the quarter.

    Cost of sales increased by $1.6 million, or 97%, to $3.3 million for the three months ended December 31, 2011, from $1.7 million for the three months ended December 31, 2010. The increase for the three months ended December 31, 2011 is primarily due to a $1.0 million charge to reserve for excess KRYSTEXXA inventory. In addition, cost of sales increased from the prior year quarter due to royalty and sales based milestones pursuant to our third party license and grant agreements, as a result of the commercialization and commencement of sales of KRYSTEXXA in 2011.

    Research and development expenses decreased by $2.3 million, or 24%, to $7.5 million for the three months ended December 31, 2011, from $9.8 million for the three months ended December 31, 2010. The decrease for the three months ended December 31, 2011 was primarily due to prior year process technology transfer expenses to facilitate the implementation of our potential secondary source supplier, partially offset by expenses incurred the current quarter associated with our KRYSTEXXA post marketing studies.

    Selling, general and administrative expe
    '/>"/>

    SOURCE Savient Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Savient Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
    2. Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
    3. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
    4. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
    5. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
    6. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
    7. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
    8. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
    9. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
    10. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
    11. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, Inc. ... music products, today announced that it has signed ... manufacturer and supplier of innovative prosthetic, orthotic and ... part of the agreement, RSL Steeper will promote ... specifically configured for use within UK residential care ...
    (Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ... Patent and Trademark Office (USPTO) has issued a ... dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens ... of US Patent No. 8,871,211, which issued October ... by administering a dendritic cell composition comprising peptide ...
    (Date:12/17/2014)... , Dec. 17, 2014  RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today announced completion of enrollment in its first Phase ... 3-month observations confirmed the 1-month findings that were ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , ...
    Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
    ... CITY, Calif., Jan. 4, 2011 Arstasis is pleased ... to physicians, nurses, patients, and cath lab technicians across ... of physicians participating in Arstasis clinical trials and select ...  As of today, the company is making the simple-to-use, ...
    ... 4, 2011 Isis Pharmaceuticals, Inc. (Nasdaq: ... Recent Advances in Isis, Development PipelineWhen: , Thursday, ... 9:00 a.m. PTWhere: , www.isispharm.comHow: , Live on ... listed above. Contacts: , Kristina LemonidisDirector, Investor Relations(760) ...
    Cached Medicine Technology:Nationwide Launch of Arstasis One Access Device Provides Cath Labs Across the U.S. an Alternative to Standard Arteriotomies and Vascular Closure Implants 2
    (Date:12/15/2014)... Cancer researchers have just published an important new report ... pleural mesothelioma. Surviving Mesothelioma has just posted an article ... to read it now. , Doctors at Harvard, ... York’s Langone Medical Center performed complete genetic analyses on ... effort to pinpoint the genes that are most likely ...
    (Date:12/15/2014)... SIMpalm, a leading mobile app development company , ... client, which allows users to keep track of wines ... the right wine. At the center of WineMatch ... and wine information. All this information is assembled to ... that are close counterparts to one another are called ...
    (Date:12/15/2014)... 14, 2014 (HealthDay News) -- Expert pilots process visual ... why they make better decisions during landings, a new ... difficult techniques for pilots to master, and 36 percent ... crashes occur during final approach and landing. Researchers ... 12 moderately experienced pilots while they were at the ...
    (Date:12/15/2014)... In support of high-quality independent peer ... state laws that may have unintended consequences through ... of public health policy. , The position paper, ... Independent Review, contends that state legislation that restricts ... determinations can result in subpar outcomes for both ...
    (Date:12/15/2014)... For the second year in a row, Bird Rock ... 2014.” Bird Rock Coffee Roasters’ Sumatra Ulos Batak came in ... 10. This is the first year that any roaster made ... on quality, value, and other aspects, including certifications and distinct ... and at $17.99 for 12-ounces, was also the most affordable ...
    Breaking Medicine News(10 mins):Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News:Study Shows Why Expert Pilots Are Experts 2Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
    ... Calif., March 26 Endocare, Inc.,(Nasdaq: ENDO ), ... minimally invasive technologies for tissue and tumor,ablation, today announced ... the B. Riley & Co. 9th Annual Las Vegas ... Friday, April 4, 2008. The conference is,being held at ...
    ... CAMPAIGN KICKS OFF TODAY, LOS ANGELES, March 26 ... the American Academy of Neurology,(AAN), the American College of ... is raising awareness about the warning signs,of stroke and ... a campaign called "Give Me 5: Walk, Talk, Reach, ...
    ... LOUIS, March 25 KV Pharmaceutical Company,(NYSE: ... that,develops, manufactures, acquires and markets technology differentiated,branded ... of its fiscal 2007 Form 10-K with ... includes restatements of previously reported results for,fiscal ...
    ... 25 As Americans get a "wake-up call",about ... men with type 2,diabetes to know that they ... men., Listen to this report from Solvay ... access video, audio, text, graphics and,photos for free ...
    ... March 25 Author and Patient,Advocate Teri Robert ... --,she,s been experiencing headaches and migraine attacks herself ... help those in,the migraine community, Robert, in conjunction ... the launch of the,"Putting Our Heads Together" Poetry ...
    ... COLUMBUS, Ohio A new study reviewing 75 group-randomized ... than half of those studies used appropriate statistical methods ... trials may have reported that interventions to prevent disease ... they might not have been. , More than a ...
    Cached Medicine News:Health News:Endocare to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference 2Health News:Morgan Fairchild Joins Neurologists, Emergency Physicians and the American Stroke Association to Educate the Public About Stroke Symptoms 2Health News:Morgan Fairchild Joins Neurologists, Emergency Physicians and the American Stroke Association to Educate the Public About Stroke Symptoms 3Health News:Morgan Fairchild Joins Neurologists, Emergency Physicians and the American Stroke Association to Educate the Public About Stroke Symptoms 4Health News:KV Pharmaceutical Company Completes Financial Restatement with the Filing of Fiscal 2007 Form 10-K 2Health News:KV Pharmaceutical Company Completes Financial Restatement with the Filing of Fiscal 2007 Form 10-K 3Health News:KV Pharmaceutical Company Completes Financial Restatement with the Filing of Fiscal 2007 Form 10-K 4Health News:MyMigraineConnection.com and Migraine Expert Teri Robert Announce Seventh Annual Migraine and Headache Poetry Contest 2Health News:MyMigraineConnection.com and Migraine Expert Teri Robert Announce Seventh Annual Migraine and Headache Poetry Contest 3Health News:Review of group-based cancer trials reveals flaws in studies' design and analysis 2Health News:Review of group-based cancer trials reveals flaws in studies' design and analysis 3
    SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
    Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
    Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
    ... Many special order products are offered ... extra long lengths. The modular instruments may ... other options such as ratchets, insulation and ... from Mediflex stock. Customer specifications may affect ...
    Medicine Products: